PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31500290-5	2019	We determined that the HDAC1/2/3 inhibitor Mocetinostat synergizes with the HDAC4/5/6 inhibitor LMK-235 in a panel of PDAC cell lines.	mocetinostat	43-55	histone deacetylase 1	Homo sapiens	23-32	
18413790-4	2008	We have developed an isotype-selective HDAC inhibitor, MGCD0103, which potently targets human HDAC1 but also has inhibitory activity against HDAC2, HDAC3, and HDAC11 in vitro.	mocetinostat	55-63	histone deacetylase 1	Homo sapiens	94-99	
22818799-3	2012	More complex second generation HDACIs undergoing clinical trials, such as the benzamide group compounds MS-275 and MGCD0103, are specific primarily for HDAC1 and HDAC2.	mocetinostat	115-123	histone deacetylase 1	Homo sapiens	152-157	
25341045-4	2014	Further, knockdown of HDAC1 in leukemia cells K562, HL-60, and U937 significantly increased Klf4 expression and inhibited cell cycle progression and cell proliferation, similar results were found for HDAC inhibitors (VPA and mocetinostat).	mocetinostat	225-237	histone deacetylase 1	Homo sapiens	22-27	
17868033-6	2008	MS-275 was HDAC1-selective, MGCD0103 was HDAC1- and HDAC2-selective, apicidin was HDAC2- and HDAC3-selective and valproic acid was a specific inhibitor of class I HDACs.	mocetinostat	28-36	histone deacetylase 1	Homo sapiens	41-46	
17455259-4	2007	In contrast, the benzamides CI994, MS275 and MGCD0103 are more selective, potent inhibitors of at least HDAC1 and HDAC3.	mocetinostat	45-53	histone deacetylase 1	Homo sapiens	104-109